Risk factors and prophylaxis for nocardiosis in solid organ transplant recipients : A nested case-control study
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
BACKGROUND: Nocardia is an opportunistic pathogen that primarily affects immunocompromised individuals, including solid organ transplant (SOT) recipients. Up to 2.65% of SOT recipients develop nocardiosis; however, few studies have examined risk factors and prophylaxis for nocardiosis.
METHODS: We performed a multicenter, matched nested case-control study of adult SOT recipients with culture-confirmed nocardiosis from 2000 through 2020. Controls were matched up to 2:1 by sex, first transplanted organ, year of transplant, transplant center, and adequate post-transplant follow-up. Multivariable conditional logistic regression was performed to analyze associations with nocardiosis. Cox proportional hazards regression compared 12-month mortality between infection and uninfected patients.
RESULTS: One hundred and twenty-three SOT recipients were matched to 245 uninfected controls. Elevated calcineurin inhibitor level, acute rejection, cytomegalovirus infection, lymphopenia, higher prednisone dose, and older age were significantly associated with nocardiosis while trimethoprim-sulfamethoxazole prophylaxis was protective (odds ratio [OR] .34; 95% confidence interval [CI] .13-.84). The effect of prophylaxis was similar, though not always statistically significant, in sensitivity analyses that only included prophylaxis dosed more than twice-per-week (OR .30; 95% CI .11-.80) or restricted to years 2015-2020 (OR .33, 95% CI .09-1.21). Nocardiosis was associated with increased 12-month mortality (hazard ratio 5.47; 95% confidence interval 2.42-12.35).
CONCLUSIONS: Multiple measures of immunosuppression and lack of trimethoprim-sulfamethoxazole prophylaxis were associated with nocardiosis in SOT recipients. Effectiveness of prophylaxis may be related to trimethoprim-sulfamethoxazole dose or frequency. Trimethoprim-sulfamethoxazole should be preferentially utilized over alternative agents in SOT recipients with augmented immunosuppression or signs of heightened immunocompromise.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
---|---|
Enthalten in: |
Clinical transplantation - 37(2023), 9 vom: 20. Sept., Seite e15016 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Yetmar, Zachary A [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 08.09.2023 Date Revised 11.09.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/ctr.15016 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM356735583 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM356735583 | ||
003 | DE-627 | ||
005 | 20231226071110.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/ctr.15016 |2 doi | |
028 | 5 | 2 | |a pubmed24n1189.xml |
035 | |a (DE-627)NLM356735583 | ||
035 | |a (NLM)37170686 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Yetmar, Zachary A |e verfasserin |4 aut | |
245 | 1 | 0 | |a Risk factors and prophylaxis for nocardiosis in solid organ transplant recipients |b A nested case-control study |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 08.09.2023 | ||
500 | |a Date Revised 11.09.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
520 | |a BACKGROUND: Nocardia is an opportunistic pathogen that primarily affects immunocompromised individuals, including solid organ transplant (SOT) recipients. Up to 2.65% of SOT recipients develop nocardiosis; however, few studies have examined risk factors and prophylaxis for nocardiosis | ||
520 | |a METHODS: We performed a multicenter, matched nested case-control study of adult SOT recipients with culture-confirmed nocardiosis from 2000 through 2020. Controls were matched up to 2:1 by sex, first transplanted organ, year of transplant, transplant center, and adequate post-transplant follow-up. Multivariable conditional logistic regression was performed to analyze associations with nocardiosis. Cox proportional hazards regression compared 12-month mortality between infection and uninfected patients | ||
520 | |a RESULTS: One hundred and twenty-three SOT recipients were matched to 245 uninfected controls. Elevated calcineurin inhibitor level, acute rejection, cytomegalovirus infection, lymphopenia, higher prednisone dose, and older age were significantly associated with nocardiosis while trimethoprim-sulfamethoxazole prophylaxis was protective (odds ratio [OR] .34; 95% confidence interval [CI] .13-.84). The effect of prophylaxis was similar, though not always statistically significant, in sensitivity analyses that only included prophylaxis dosed more than twice-per-week (OR .30; 95% CI .11-.80) or restricted to years 2015-2020 (OR .33, 95% CI .09-1.21). Nocardiosis was associated with increased 12-month mortality (hazard ratio 5.47; 95% confidence interval 2.42-12.35) | ||
520 | |a CONCLUSIONS: Multiple measures of immunosuppression and lack of trimethoprim-sulfamethoxazole prophylaxis were associated with nocardiosis in SOT recipients. Effectiveness of prophylaxis may be related to trimethoprim-sulfamethoxazole dose or frequency. Trimethoprim-sulfamethoxazole should be preferentially utilized over alternative agents in SOT recipients with augmented immunosuppression or signs of heightened immunocompromise | ||
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Nocardia | |
650 | 4 | |a calcineurin inhibitor | |
650 | 4 | |a disseminated infection | |
650 | 4 | |a organ transplantation | |
650 | 4 | |a trimethoprim-sulfamethoxazole | |
650 | 7 | |a Trimethoprim, Sulfamethoxazole Drug Combination |2 NLM | |
650 | 7 | |a 8064-90-2 |2 NLM | |
700 | 1 | |a Chesdachai, Supavit |e verfasserin |4 aut | |
700 | 1 | |a Duffy, Dustin |e verfasserin |4 aut | |
700 | 1 | |a Smith, Byron H |e verfasserin |4 aut | |
700 | 1 | |a Challener, Douglas W |e verfasserin |4 aut | |
700 | 1 | |a Seville, Maria Teresa |e verfasserin |4 aut | |
700 | 1 | |a Bosch, Wendelyn |e verfasserin |4 aut | |
700 | 1 | |a Beam, Elena |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical transplantation |d 1987 |g 37(2023), 9 vom: 20. Sept., Seite e15016 |w (DE-627)NLM07493306X |x 1399-0012 |7 nnns |
773 | 1 | 8 | |g volume:37 |g year:2023 |g number:9 |g day:20 |g month:09 |g pages:e15016 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/ctr.15016 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 37 |j 2023 |e 9 |b 20 |c 09 |h e15016 |